The objective of this study was to test the correlation of urinary podocyte number (U-Pod) and urinary podocalyxin levels (U-PCX) with histology of lupus nephritis.
Methods
This was an observational, cross-sectional study. Sixty-four patients were enrolled: 40 with lupus nephritis and 24 without lupus nephritis (12 lupus nephritis patients in complete remission and 12 systemic lupus erythematosus patients without lupus nephritis). Urine samples were collected before initiating treatment. U-Pod was determined by counting podocalyxin-positive cells, and U-PCX was measured by sandwich ELISA, normalized to urinary creatinine levels (U-Pod/Cr, U-PCX/Cr).
Results
Lupus nephritis patients showed significantly higher U-Pod/Cr and U-PCX/Cr compared with patients without lupus nephritis. U-Pod/Cr was high in proliferative lupus nephritis (class III±V/IV±V), especially in pure class IV (4.57 (2.02–16.75)), but low in pure class V (0.30 (0.00–0.71)). U-Pod/Cr showed a positive correlation with activity index (r=0.50, P=0.0012) and was independently associated with cellular crescent formation. In contrast, U-PCX/Cr was high in both proliferative and membranous lupus nephritis. Receiver operating characteristic analysis revealed significant correlation of U-Pod/Cr with pure class IV, class IV±V and cellular crescent formation, and the combined values of U-Pod/Cr and U-PCX/Cr were shown to be associated with pure class V.
Conclusions
U-Pod/Cr and U-PCX/Cr correlate with histological features of lupus nephritis.
JakesRWBaeSCLouthrenooWet al.Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken)2012; 64: 159–168.
2.
BonoLCameronJSHicksJA. The very long-term prognosis and complications of lupus nephritis and its treatment. QJM1999; 92: 211–218.
3.
CerveraRKhamashtaMAFontJet al.Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore)2003; 82: 299–308.
4.
AppelGBCohenDJPiraniCLet al.Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. Am J Med1987; 83: 877–885.
5.
YokoyamaHOkuyamaHYamayaH. Clinicopathological insights into lupus glomerulonephritis in Japanese and Asians. Clin Exp Nephrol2011; 15: 321–330.
6.
WeeningJJD’AgatiVDSchwartzMMet al.The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol2004; 15: 241–250.
7.
YokoyamaHWadaTHaraAet al.The outcome and a new ISN/RPS 2003 classification of lupus nephritis in Japanese. Kidney Int2004; 66: 2382–2388.
8.
HiramatsuNKuroiwaTIkeuchiHet al.Revised classification of lupus nephritis is valuable in predicting renal outcome with an indication of the proportion of glomeruli affected by chronic lesions. Rheumatology (Oxford)2008; 47: 702–707.
9.
SisoARamos-CasalsMBoveAet al.Outcomes in biopsy-proven lupus nephritis: evaluation of 190 white patients from a single center. Medicine (Baltimore)2010; 89: 300–307.
10.
HwangJKimHJOhJMet al.Outcome of reclassification of World Health Organization (WHO) class III under International Society of Nephrology–Renal Pathology Society (ISN–RPS) classification: retrospective observational study. Rheumatol Int2012; 32: 1877–1884.
11.
IkeuchiHHiromuraKKayakabeKet al.Renal outcomes in mixed proliferative and membranous lupus nephritis (class III/IV + V): a long-term observational study. Mod Rheumatol. Epub ahead of print 26 April 2016; 1–6. DOI: 10.3109/14397595.2016.1158896.
12.
HiromuraKIkeuchiHKayakabeKet al.Clinical and histological features of lupus nephritis in Japan: a cross-sectional analysis of the Japan Renal Biopsy Registry (J-RBR). Nephrology (Carlton). Epub ahead of print 26 June 2016. DOI: 10.1111/nep.12863.
13.
YuFWuLHTanYet al.Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system. Kidney Int2010; 77: 820–829.
14.
YuFTanYLiuGet al.Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis. Kidney Int2009; 76: 307–317.
15.
HahnBHMcMahonMAWilkinsonAet al.American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken)2012; 64: 797–808.
16.
BertsiasGKTektonidouMAmouraZet al.Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis2012; 71: 1771–1782.
17.
GroupKGW. KDIGO Clinical Practice Guideline for Glomerulonephritis. Chapter 12: Lupus nephritis. Kidney Int2012(Suppl 2): 221–232.
18.
DrumondMCDeenWM. Structural determinants of glomerular hydraulic permeability. Am J Physiol1994; 266: F1–12.
19.
KrizWGretzNLemleyKV. Progression of glomerular diseases: is the podocyte the culprit?Kidney Int1998; 54: 687–697.
20.
HaraMYanagiharaTKiharaI. Cumulative excretion of urinary podocytes reflects disease progression in IgA nephropathy and Schonlein–Henoch purpura nephritis. Clin J Am Soc Nephrol2007; 2: 231–238.
21.
NakamuraTUshiyamaCSuzukiSet al.Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant2000; 15: 1379–1383.
22.
HaraMYamagataKTominoYet al.Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin. Diabetologia2012; 55: 2913–2919.
23.
NielsenJSMcNagnyKM. The role of podocalyxin in health and disease. J Am Soc Nephrol2009; 20: 1669–1676.
24.
HaraMYanagiharaTKiharaIet al.Apical cell membranes are shed into urine from injured podocytes: a novel phenomenon of podocyte injury. J Am Soc Nephrol2005; 16: 408–416.
25.
HaraMYanagiharaTHirayamaYet al.Podocyte membrane vesicles in urine originate from tip vesiculation of podocyte microvilli. Hum Pathol2010; 41: 1265–1275.
NakamuraTUshiyamaCSuzukiSet al.Urinary podocytes for the assessment of disease activity in lupus nephritis. Am J Med Sci2000; 320: 112–116.
28.
AsaoRAsanumaKKodamaFet al.Relationships between levels of urinary podocalyxin, number of urinary podocytes, and histologic injury in adult patients with IgA nephropathy. Clin J Am Soc Nephrol2012; 7: 1385–1393.
29.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725–1725.
30.
AustinHAIIIMuenzLRJoyceKMet al.Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int1984; 25: 689–695.
31.
Perez-HernandezJOlivaresMDFornerMJet al.Urinary dedifferentiated podocytes as a non-invasive biomarker of lupus nephritis. Nephrol Dial Transplant2016; 31: 780–789.
32.
WangPLiMLiuQet al.Detection of urinary podocytes and nephrin as markers for children with glomerular diseases. Exp Biol Med (Maywood)2015; 240: 169–174.
33.
KuboKMiyagawaKYamamotoRet al.Detection of WT1 mRNA in urine from patients with kidney diseases. Eur J Clin Invest1999; 29: 824–826.
34.
ZhouHCheruvankyAHuXet al.Urinary exosomal transcription factors, a new class of biomarkers for renal disease. Kidney Int2008; 74: 613–621.
35.
SzetoCCWangGChowKMet al.Podocyte mRNA in the urinary sediment of minimal change nephropathy and focal segmental glomerulosclerosis. Clin Nephrol2015; 84: 198–205.
36.
WickmanLAfshinniaFWangSQet al.Urine podocyte mRNAs, proteinuria, and progression in human glomerular diseases. J Am Soc Nephrol2013; 24: 2081–2095.
37.
MansurJBSabinoARNishidaSKet al.Is there a role for urinary podocyte excretion assessment in lupus nephritis?Ren Fail2016; 38: 643–647.
38.
MayCJSaleemMWelshGI. Podocyte dedifferentiation: a specialized process for a specialized cell. Front Endocrinol (Lausanne)2014; 5: 148–148.
39.
VogelmannSUNelsonWJMyersBDet al.Urinary excretion of viable podocytes in health and renal disease. Am J Physiol Renal Physiol2003; 285: F40–F48.
40.
ImaizumiTNakatochiMAkiyamaSet al.Urinary podocalyxin as a biomarker to diagnose membranous nephropathy. PLoS One2016; 11: e0163507–e0163507.
41.
IwanoMDohiKHirataEet al.Urinary levels of IL-6 in patients with active lupus nephritis. Clin Nephrol1993; 40: 16–21.
42.
WadaTYokoyamaHSuSBet al.Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. Kidney Int1996; 49: 761–767.
43.
WatsonLMidgleyAPilkingtonCet al.Urinary monocyte chemoattractant protein 1 and alpha 1 acid glycoprotein as biomarkers of renal disease activity in juvenile-onset systemic lupus erythematosus. Lupus2012; 21: 496–501.
44.
LeeYHSongGG. Urinary MCP-1 as a biomarker for lupus nephritis: a meta-analysis. Z Rheumatol. Epub ahead of print 9 June 2016. DOI: 10.1007/s00393-016-0109-z.
45.
XuejingZJiazhenTJunLet al.Urinary TWEAK level as a marker of lupus nephritis activity in 46 cases. J Biomed Biotechnol2012; 2012: 359647–359647.
46.
EndoNTsuboiNFuruhashiKet al.Urinary soluble CD163 level reflects glomerular inflammation in human lupus nephritis. Nephrol Dial Transplant2016; 31: 2023–2033.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
